Milan Chandravadan Satia

Milan Chandravadan Satia

Active Director Director DIN 07114756
DIN 07114756 First appointment Oct 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Oct 2020
Shareholding value •••• Premium profile

About Milan Chandravadan Satia

Data last updated:

Milan Chandravadan Satia is a Director at Ethicare Clinical Trial Services (Opc) Private Limited (since 2020). The company operates in Pharma. Ethicare Clinical Trial Services (Opc) Private Limited reported revenue of ₹6.52 Cr (FY 2025).

DIN 07114756
Primary Designation Director
Industry Pharma
First Appointment 16 Oct 2020
Oldest Company Age 6 yrs
Largest company Ethicare Clinical Trial Services (Opc) Private Limited · ₹6.52 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director16 Oct 20202020₹6.52 Cr (FY 2025)Active

Directorship timeline

Open interactive timeline →
Ethicare Clinical Trial Services (Opc) Private Limited
Premium access

Shareholding and investment profile for Milan Chandravadan Satia

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Milan Chandravadan Satia

Milan Chandravadan Satia currently holds 1 directorship: Ethicare Clinical Trial Services (Opc) Private Limited (Director, since 16 Oct 2020, revenue ₹6.52 Cr (FY 2025)).

Milan Chandravadan Satia was first appointed on 16 Oct 2020 as Director at Ethicare Clinical Trial Services (Opc) Private Limited.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available